Clinical Trial Update: A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN) [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy trial evaluating fondaparinux in percutaneous coronary intervention has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Myocardial Infarction

Drugs mentioned

• Fondaparinux (fondaparinux)

Snippet

Sponsor: Schering-Plough | Conditions: Myocardial Infarction, Coronary Disease | Phase 2 | Status: WITHDRAWN